FDA approves cryopreserved ReNeuron formulation

Josh White Sharecast | 19 Jun, 2017 12:54 - Updated: 12:54 | | |

Astrazeneca

ReNeuron Group

1.95

17:18 18/08/17
0.00%
0.00
  • 12,633.60
  • -1.35%-172.25
  • Max: 12,805.85
  • Min: 12,584.26
  • Volume: 0
  • MM 200 : n/a
17:25 18/08/17
  • 999.29
  • -0.30%-3.03
  • Max: 1,002.78
  • Min: 997.68
  • Volume: 0
  • MM 200 : n/a
17:30 18/08/17

Cell-based therapeutics developer ReNeuron Group updated the marker on its cell therapy development programmes targeting degenerative diseases of the retina on Monday, reporting that the US Food and Drug Administration (FDA) had approved the cryopreserved formulation of its human retinal progenitor cell (hRPC) therapeutic candidate.

The AIM-traded firm said that as a result, it had now started treating patients with the formulation in its ongoing US Phase I/II study clinical trial in retinitis pigmentosa (RP) patients.

It said the new proprietary formulation enabled the hRP cells to be frozen for shipping and storage, and easily thawed at the point of clinical use.

That freeze-thaw modality reportedly provided a “greatly enhanced” shelf life for the product, lower prospective cost of goods and the capability to ship the cells for clinical and commercial application anywhere in the world.

The new hRPC formulation had also facilitated an expansion of ReNeuron's clinical programmes in ophthalmology, the board claimed.

As it had previously announced, the company was set to shortly file an application with the FDA to expand the Phase II element of the ongoing Phase I/II clinical trial in RP from six to 20 patients.

The expanded study was designed to provide the “depth and quality” of data that, if positive, would allow subsequent progression to a Phase II/III pivotal study in the indication.

ReNeuron’s board said it also intended to file an application to start a new US Phase II clinical trial later in the year in patients with cone-rod dystrophy, to be conducted alongside the Phase II part of the ongoing RP clinical trial.

“We are delighted that the FDA has approved the use of the cryopreserved formulation of our hRPC retinal cell therapy candidate in our ongoing clinical development programmes,” said ReNeuron CEO Olav Hellebø.

“This is a further significant milestone for ReNeuron, enabling an expansion of our clinical programmes in ophthalmology as well as providing ReNeuron with a significant commercial advantage in terms of prospective cost of goods and ease of use of a retinal disease therapy.”

More news

17:27 Weeky review

The FTSE 100 finished the week almost flat, up 17.5 points or 0.24%, at 7,323.98.

17:22 London close: Risk aversion grips FTSE, stocks lower on Trump and Barcelona attacks

London's FTSE 100 index fell below a key technical level as Friday's session wore on, with travel stocks leading the retreat after the terror attacks in Barcelona and the large cabal of overseas focused companies hit by the dollar's weakness amid renewed concerns about the US Presidency.

17:03 BowLeven appoints new director

AIM-listed oil and gas group, BowLeven announced on Friday that Matt McDonald would be appointed to the firm's board as non-executive director with immediate effect.

17:04 Week ahead: Not everything that happens at Jackson Hole stays there

In the coming week, the spotlight will be on the Federal Reserve bank of Kansas City's Symposium in Jackson Hole, Wyoming.

16:26 Acacia remains a 'buy' for HSBC but target price slashed

HSBC cut its target price for Acacia Mining by 47% but kept its 'buy' recommendation in place as the months-long spat with the Tanzanian government still hangs over the company.

16:10 US open: Stocks flat heading into the weekend, political ruckus weighs

Wall Street is essentially flat heading into the weekend after the head of the University of Michigan's consumer confidence survey said recent events in Charlottesville were likely to take their toll on sentiment.

15:18 FTSE 250 movers: Hikma still looking ill; Kaz Minerals buffs up

Hikma Pharmaceuticals shares continued their downward spiral as HSBC slashed their target price, telling clients its first half numbers contained lower guidance for generics and a tougher outlook for injectables and branded drugs.

14:56 Calpine agrees to be acquired for $5.6bn in cash

Shares of Calpine Corporation surged after news broke that the American power generation company had agreed to be acquired by a consortium led by Energy Capital Partners.

14:27 FTSE 100 movers: Airline shares down after Barcelona attack; Upgrade boost for Mondi, RSA

The Barcelona attack and disintegrating relationship between US President Donald Trump and the business community made for a very heavy splash of red among the Footsie on Friday.

14:16 AppScatter eyes IPO in early September

AppScatter Group, a mobile app distribution and management platform, is drumming up institutional investor support for a flotation on London's AIM market in early September.